Lynch Syndrome Molecular Diagnosis

Understanding Lynch Syndrome: Molecular Diagnosis and Genetic Counseling

Lynch syndrome, also known as hereditary non‑polyposis colorectal cancer (HNPCC), is the most common inherited cause of colorectal cancer (CRC) and is associated with an increased risk of several other malignancies. Accurate molecular diagnosis is essential for guiding patient management, family screening, and therapeutic decisions. This course explores the key laboratory tests, inheritance patterns, and variant classification criteria used in the evaluation of suspected Lynch syndrome.

1. Immunohistochemistry (IHC) and the Role of MLH1/PMS2 Loss

Immunohistochemistry is often the first step in tumor screening. The mismatch repair (MMR) proteins—MLH1, PMS2, MSH2, and MSH6—are evaluated for loss of expression. When a tumor shows loss of MLH1 and PMS2, the underlying cause can be either a germline mutation (Lynch syndrome) or a sporadic epigenetic event.

Distinguishing Sporadic from Hereditary Cases

The most appropriate follow‑up test is methylation‑specific PCR of the MLH1 promoter. Promoter hypermethylation silences MLH1 in sporadic CRC, leading to loss of both MLH1 and PMS2 on IHC. In contrast, germline mutations typically do not show promoter methylation.

• Why not BRAF V600E testing? BRAF mutation is a surrogate marker for sporadic MLH1 methylation but is not definitive; promoter methylation directly assesses the epigenetic change.
• Why not MSI testing? Microsatellite instability (MSI) is useful but does not differentiate between somatic and germline causes when MLH1 loss is already known.
• Why not sequencing MSH2? The IHC pattern points to the MLH1/PMS2 axis, making MSH2 sequencing low yield.

2. Inheritance Patterns in Lynch Syndrome

Lynch syndrome follows an autosomal dominant inheritance pattern. Each first‑degree relative of a carrier has a 50% chance of inheriting the pathogenic allele, regardless of sex.

Key features of autosomal dominant transmission include:

• Vertical transmission across generations.
• Both males and females can be affected and can transmit the mutation.
• Variable penetrance: not all carriers develop cancer, but risk is markedly increased.

Other inheritance models—X‑linked dominant, mitochondrial, and autosomal recessive—do not fit the observed 50% risk pattern and have distinct clinical signatures.

3. Microsatellite Instability (MSI) and IHC Discordance

MSI‑High status indicates a defective MMR system, yet a tumor may retain expression of all four MMR proteins on IHC. The most plausible explanation for this discordance is a technical false‑negative IHC result due to low tumor cellularity.

Factors contributing to false‑negative IHC include:

• Insufficient tumor cells in the tissue section.
• Suboptimal antigen retrieval or antibody performance.
• Interpretation errors by the pathologist.

When MSI‑High is observed, repeat IHC on a different block or use alternative methods (e.g., next‑generation sequencing) to confirm MMR deficiency.

4. Population Frequencies of MMR Gene Mutations

Understanding the baseline prevalence of pathogenic variants helps clinicians interpret genetic test results. The frequencies reported for the general population are approximately:

• MLH1: 0.051%
• MSH2: 0.035%
• MSH6: 0.132%
• PMS2: 0.140%

These low frequencies underscore the rarity of germline mutations and the importance of accurate phenotypic screening before proceeding to comprehensive genetic testing.

5. Variant Classification: The ACMG/ClinVar Framework

When a variant such as c.3984_3987dup (p.Leu1330fs) in the PMS2 gene is identified, its clinical significance is classified using the American College of Medical Genetics and Genomics (ACMG) guidelines, which align with ClinVar categories:

• Class‑1: Benign
• Class‑2: Likely benign
• Class‑3: Variant of uncertain significance (VUS)
• Class‑4: Likely pathogenic
• Class‑5: Pathogenic

Frameshift mutations that lead to premature termination and loss of protein function, especially when supported by functional studies, are typically classified as Class‑5 (pathogenic). This classification informs clinical decisions such as initiating surveillance protocols for the patient and offering cascade testing to relatives.

6. Integrated Diagnostic Algorithm for Suspected Lynch Syndrome

Below is a step‑by‑step algorithm that combines the concepts discussed:

1. Screening: Perform IHC for MLH1, PMS2, MSH2, and MSH6 on tumor tissue.
2. Interpret IHC results:
   • If loss of MLH1/PMS2 → test MLH1 promoter methylation.
   • If loss of MSH2/MSH6 → proceed directly to germline sequencing of the corresponding genes.
   • If all proteins retained but MSI‑High → repeat IHC or use alternative assays.
3. MSI testing: Use the Bethesda panel (BAT25, BAT26, NR21, NR24, MONO27) to confirm MSI‑High status when IHC is ambiguous.
4. Germline testing: Sequence the relevant MMR genes; include EPCAM deletion analysis if MLH1 loss is unexplained.
5. Variant interpretation: Apply ACMG criteria; consider functional data, population frequency, and segregation analysis.
6. Genetic counseling: Discuss autosomal dominant inheritance, 50% risk to first‑degree relatives, and recommend colonoscopic surveillance starting at age 20‑25 for carriers.

7. Clinical Implications and Management

Accurate molecular diagnosis influences several aspects of patient care:

• Surveillance: Colonoscopy every 1–2 years, endometrial sampling for women, and consideration of other organ-specific screenings.
• Treatment: MSI‑High tumors may respond better to immune checkpoint inhibitors (e.g., pembrolizumab).
• Family testing: Cascade testing allows at‑risk relatives to undergo predictive testing and enter appropriate surveillance programs.

8. Frequently Asked Questions (FAQ)

Q: Why is promoter methylation testing preferred over BRAF mutation analysis?

A: While BRAF V600E mutation is a surrogate marker for sporadic MLH1 methylation, direct methylation testing provides definitive evidence of epigenetic silencing, reducing false‑positive referrals for germline testing.

Q: Can a pathogenic EPCAM deletion cause MLH1 loss?

Yes. Deletions upstream of EPCAM can lead to transcriptional read‑through and subsequent silencing of the adjacent MLH1 gene, mimicking the IHC pattern of MLH1 loss.

Q: How should a VUS be managed?

Variants of uncertain significance should not be used for clinical decision‑making until additional evidence (functional assays, segregation data) reclassifies them as likely benign or pathogenic.

9. Summary

Effective diagnosis of Lynch syndrome integrates immunohistochemistry, MSI testing, promoter methylation analysis, and comprehensive germline sequencing. Understanding the autosomal dominant inheritance pattern and applying rigorous variant classification ensures that patients receive appropriate surveillance and that families benefit from accurate risk assessment.